Cybin Company Description

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

The company is headquartered in Toronto, Canada.

Cybin Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	50
CEO	Douglas Drysdale

Contact Details

Address: 100 King Street West Toronto, Ontario M5X 1C9 Canada
Website	cybin.com

Stock Details

Ticker Symbol	CYBN
Exchange	Cboe Canada
Fiscal Year	April - March
Reporting Currency	CAD
ISIN Number	CA23256X1006
SIC Code	2834

Key Executives

Name	Position
Douglas L. Drysdale	Chief Executive Officer
Eric So L.L.B.	Co-Founder, President and Executive Chairman
Paul Glavine	Co-Founder, Chief Growth Officer and Director
Greg Cavers	Chief Financial Officer
Aaron Bartlone	Chief Operating Officer
George Tziras	Chief Business Officer and Director
John Kanakis	Co-Founder
Dr. Alex L. Nivorozhkin Ph.D.	Chief Scientific Officer
Lori Challenger	Chief Compliance, Ethics and Administrative Officer
Gabriel Fahel	Chief Legal Officer and Corporate Secretary